{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:37:37Z","timestamp":1794335857893,"version":"4.9.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The immune system of people living with HIV (PLWH) is persistently exposed to antigens leading to systemic inflammation despite combination antiretroviral treatment (cART). This inflammatory milieu promotes T-cell activation and exhaustion. Furthermore, it produces diminished effector functions including loss of cytokine production, cytotoxicity, and proliferation, leading to disease progression. Exhausted T cells show overexpression of immune checkpoint molecules (ICs) on the cell surface, including programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), and lymphocyte activation gene-3 (LAG-3). The ICs also play a crucial role in T-cell exhaustion by reducing the immune response to cancer antigens. Immunotherapy based on immune checkpoint inhibitors (ICIs) has changed the management of a diversity of cancers. Additionally, the interest in exploring this approach in the setting of HIV infection has increased, including AIDS-defining cancers and non-AIDS-defining cancers in PLWH. To date, research on this topic suggests that ICI-based therapies in PLWH could be a safe and effective approach. In this review, we provide an overview of the current literature on the potential role of ICI-based immunotherapy not only in cancer remission in PLWH but also as a therapeutic intervention to restore immune response against HIV, revert HIV latency, and attain a functional cure for HIV infection.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1270881","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:12:18Z","timestamp":1701943938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV"],"prefix":"10.3389","volume":"14","author":[{"given":"Jos\u00e9 M.","family":"Benito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Foncillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Rall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: towards an HIV cure","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-092112-152941","article-title":"Understanding HIV latency: the road to an HIV cure","volume":"66","author":"Dahabieh","year":"2015","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1005661","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PloS Pathog"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-328070","article-title":"Responsiveness of HIV-specific CD4 T cells to PD-1 blockade","volume":"118","author":"Porichis","year":"2011","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PloS Pathog"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.000065","article-title":"Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation","volume":"96","author":"El-Far","year":"2015","journal-title":"J Gen Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PloS Pathog"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMc1804812","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30115-0","article-title":"Treatment management of haematological Malignancies in people living with HIV","volume":"7","author":"Re","year":"2020","journal-title":"Lancet Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103840","article-title":"Immune checkpoint blockade in HIV","volume":"76","author":"Gubser","year":"2022","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01223","article-title":"The role of immunomodulatory receptors in the pathogenesis of HIV infection: A therapeutic opportunity for HIV cure","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02339","article-title":"Targeting immune checkpoint molecules to eliminate latent HIV","volume":"9","author":"Boyer","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/COH.0000000000000328","article-title":"Cancer therapies in HIV cure research","volume":"12","author":"Rasmussen","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","article-title":"Molecular and transcriptional basis of CD4\u207a T cell dysfunction during chronic infection","volume":"40","author":"Crawford","year":"2014","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK cell exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000092","article-title":"B-cell exhaustion in HIV infection: the role of immune activation","volume":"9","author":"Moir","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402176","article-title":"The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects","volume":"194","author":"Tian","year":"2015","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/srep40354","article-title":"Perturbed CD8+ T cell TIGIT\/CD226\/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals","volume":"7","author":"Tauriainen","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1038\/ncomms9495","article-title":"Immunological biomarkers predict HIV-1 viral rebound after treatment interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181fbab9f","article-title":"Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment","volume":"56","author":"Grabmeier-Pfistershammer","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000913","article-title":"Inflammation perturbs the IL-7 axis, promoting senescence and exhaustion that broadly characterize immune failure in treated HIV infection","volume":"71","author":"Shive","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1038\/s41467-018-06843-5","article-title":"A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation","volume":"9","author":"Reeves","year":"2018","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-008-0003-7","article-title":"T-cell exhaustion in HIV infection","volume":"5","author":"El-Far","year":"2008","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy","volume":"215","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/QAD.0000000000002406","article-title":"T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy","volume":"34","author":"Macatangay","year":"2020","journal-title":"AIDS"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"B40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/hiv.13031","article-title":"HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cART","volume":"22","author":"Horn","year":"2021","journal-title":"HIV Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100766","article-title":"Memory CD4+ T cells that co-express PD-1 and CTLA-4 have reduced response to activating stimuli facilitating HIV latency","volume":"100766","author":"Rasmussen","year":"2022","journal-title":"Cell Rep Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2018","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"OF10","DOI":"10.1158\/2159-8290.CD-NB2017-053","article-title":"Atezolizumab extends survival for breast cancer","volume":"7","year":"2017","journal-title":"Cancer Discovery"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.09.017","article-title":"Nivolumab-induced colitis treated by infliximab","volume":"15","author":"Yanai","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875910","article-title":"Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases","volume":"9","author":"Aguilar-Company","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102011","article-title":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): A review of the available evidence","volume":"86","author":"Tapia Rico","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/atm-20-5207","article-title":"Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction","volume":"9","author":"Florou","year":"2021","journal-title":"Ann Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"Lancet HIV"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Jensen","year":"2023","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","article-title":"HIV-1 remission and possible cure in a woman after haplo-cord blood transplant","volume":"186","author":"Hsu","year":"2023","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005270","article-title":"PD-L1 blockade differentially impacts regulatory T cells from HIV-infected individuals depending on plasma viremia","volume":"11","author":"Peligero","year":"2015","journal-title":"PloS Pathog"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701551","article-title":"Immune checkpoint blockade restores HIV-specific CD4 T cell help for NK cells","volume":"201","author":"Porichis","year":"2018","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1348","article-title":"TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells","volume":"10","author":"Holder","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4049\/jimmunol.2100367","article-title":"Combination immune checkpoint blockade enhances IL-2 and CD107a production from HIV-specific T cells ex vivo in people living with HIV on antiretroviral therapy","volume":"208","author":"Chiu","year":"2022","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121932","article-title":"Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production","volume":"210","author":"Perreau","year":"2013","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104254","article-title":"Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function","volume":"84","author":"Brunet-Ratnasingham","year":"2022","journal-title":"EBioMedicine"},{"key":"B77","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901191","article-title":"Combination immune checkpoint blockade to reverse HIV latency","volume":"204","author":"Van der Sluis","year":"2020","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302044","article-title":"In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit","volume":"191","author":"Amancha","year":"2013","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122940","article-title":"Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV","volume":"3","author":"Mylvaganam","year":"2018","journal-title":"JCI Insight"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202148119","article-title":"PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques","volume":"119","author":"Velu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0782-y","article-title":"CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption","volume":"26","author":"Harper","year":"2020","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.8.5439","article-title":"Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection","volume":"180","author":"CecChinato","year":"2008","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122089","article-title":"Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1-infected subject treated with pembrolizumab","volume":"8","author":"Blanch-Lombarte","year":"2019","journal-title":"J Clin Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002919","article-title":"The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy","volume":"35","author":"Lau","year":"2021","journal-title":"AIDS"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1530","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS Malignancy consortium 095 study","volume":"73","author":"Rasmussen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2989048","article-title":"Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer","volume":"2019","author":"Bari","year":"2019","journal-title":"J Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002716","article-title":"Suspected immune-related adverse events with an anti-PD-1 inhibitor in otherwise healthy people with HIV","volume":"87","author":"Gay","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: A systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002397","article-title":"Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects","volume":"34","author":"Abbar","year":"2020","journal-title":"AIDS"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-international (CATCH-IT) consortium","volume":"41","author":"El Zarif","year":"2023","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.910115","article-title":"Case report: clinical characteristics and outcomes of HIV positive patients with metastatic prostate cancer treated with immunotherapy: A case series and literature review","volume":"12","author":"Idossa","year":"2022","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5228","article-title":"Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report","volume":"9","author":"Alloghbi","year":"2021","journal-title":"Clin Case Rep"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0121","article-title":"Successful treatment of HIV-associated kaposi sarcoma with immune checkpoint blockade","volume":"6","author":"Galanina","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061015","article-title":"Impact of anti PD-1 immunotherapy on HIV reservoir and anti-viral immune responses in people living with HIV and cancer","volume":"11","author":"Baron","year":"2022","journal-title":"Cells"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198158","article-title":"An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients","volume":"13","author":"Colston","year":"2018","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1270881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:12:21Z","timestamp":1701943941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1270881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2023.1270881"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1270881","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1270881"}}